Our knowledge stewardship campaign empowers students to advocate for universities to foster access and ownership of knowledge and intellectual property in a way that focuses on equity and maximises global public benefit. UAEM aims to hold universities accountable on their missions to serve the public interest. In order to achieve that, UAEM students advocate for universities to adopt Global Access Licensing Principles (GAL) in their licensing agreements for health technologies, to ensure that the end products are made affordable for people in low- and middle-income countries. Over the years, leading universities such as Harvard, Yale, Berkeley, University of British Columbia, Oxford, Bergen and others, have included statements about global access in their licensing policies. Following UAEM`s efforts, in 2009 the “Statement of Principles and Strategies for the Equitable Dissemination of Medical Technologies” was written and introduced by members of the “Association of University Technology Managers” (AUTM) and has since been endorsed by many top research institutions as well as the NIH and CDC.
UAEM also runs specific campus campaigns that target universities who are not taking adequate steps to protect access to lifesaving medical discoveries, such as the campaign to ensure that Johns Hopkins University would work to make a new tuberculosis drug accessible at an affordable price globally.
To encourage more universities to live up to their responsibility to promote and protect the public interest, UAEM created a unique tool: The University Report Card, which evaluates and compares top academic research institutions on their contributions to neglected biomedical research and access to medicines. In addition, UAEM engages with national and regional institutions such as “ASTP Proton” European technology transfer association) to create awareness and tools to advance knowledge stewardship at universities.
UAEM continues to promote licensing policies and practices that can protect access to the lifesaving health technologies discovered at universities for people living in low- and middle-income countries. Today, we have also begun to work on fighting for access for all worldwide, including in high-income countries across Europe and in Canada, the US, and Australia where high drug prices limit access to medicines for many.
If you are interested in learning more about how to advocate for adoption of Global Access Licensing (GAL) Principles at your university, check out our GAL Advocacy Guide developed by UAEM Europe.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.